Frequency of treatment-emergent sexual dysfunction and treatment effectiveness during SSRI or duloxetine therapy: 8-week data from a 6-month observational study

International Journal of Psychiatry in Clinical Practice

Volumn 15, Issue 2, 2011, Pages 80-90

  Dueñas, Hector ^a   Lee, Arier ^b   Brnabic, Alan J M ^b   Chung, Ka Fai ^c   Lai, Chien Han ^d   Badr, Mohamed Gamal ^e   Uy Ponio, Tiffany ^f   Ruiz, Jorge Rodríguez ^g   Varrey, Padmaraju ^h   Jian, Hu ⁱ   Dossenbach, Martin ^j  

^a Eli Lilly Mexico   (Mexico)

^b ELI LILLY AUSTRALIA PTY LTD   (Australia)

^c UNIVERSITY OF HONG KONG   (Hong Kong)

^d BUDDHIST TZU CHI GENERAL HOSPITAL   (Taiwan)

^e AL AZHAR UNIVERSITY   (Egypt)

^f St Claire Psychiatric Homecare ^*  (Philippines)

^g Centro Bariátrico Metabólico Dalinde Centro Médico Dalinde   (Mexico)

^h NMC SPECIALTY HOSPITAL   (United Arab Emirates)

ⁱ HARBIN MEDICAL UNIVERSITY   (China)

^j Medical Department   (Austria)

more..

Author keywords

duloxetine; Major depressive disorder (MDD); observational study; selective serotonin reuptake inhibitor (SSRI); treatment emergent sexual dysfunction (TESD)

Indexed keywords

ANXIOLYTIC AGENT; BENZODIAZEPINE; DULOXETINE; ESCITALOPRAM; FLUOXETINE; HYPNOTIC AGENT; MOOD STABILIZER; NEUROLEPTIC AGENT; PAROXETINE; SEDATIVE AGENT; SEROTONIN UPTAKE INHIBITOR; SERTRALINE;

ADULT; ARTICLE; CLINICAL GLOBAL IMPRESSION SCALE; DRUG EFFICACY; ETHNICITY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; PHYSICIAN; PRIORITY JOURNAL; PSYCHOTHERAPY; QUALITY OF LIFE; QUICK INVENTORY DEPRESSIVE SYMPTOMATOLOGY; SELF REPORT; SEXUAL DYSFUNCTION; TREATMENT EMERGENT SEXUAL DYSFUNCTION; TREATMNET EMERGENT SEXUAL DYSFUNCTION;

ADRENERGIC UPTAKE INHIBITORS; ADULT; DEPRESSIVE DISORDER, MAJOR; FEMALE; HUMANS; MALE; MIDDLE AGED; QUALITY OF LIFE; SEROTONIN UPTAKE INHIBITORS; SEXUAL DYSFUNCTIONS, PSYCHOLOGICAL; THIOPHENES;

EID: 79955783327     PISSN: 13651501     EISSN: 14711788     Source Type: Journal    
DOI: 10.3109/13651501.2011.572169     Document Type: Article

References (27)

1. Kennedy SH, Eisfeld BS, Dickens SE, Bacchiochi JR, Bagby RM. Antidepressant-induced sexual dysfunction during treatment with moclobemide, paroxetine, sertraline, and venlafaxine. J Clin Psychiatry 2000;61:276-81. (Pubitemid 30305369)
2. Montejo AL, Llorca G, Izquierdo JA, Rico-Villademoros F. Incidence of sexual dysfunction associated with antidepressant agents: a prospective multicenter study of 1022 outpatients. Spanish Working Group for the Study of Psychotropic-Related Sexual Dysfunction. J Clin Psychiatry 2001;62(Suppl 3): 10-21. (Pubitemid 32164676)
3. Gregorian RS, Golden KA, Bahce A, Goodman C, Kwong WJ, Khan ZM. Antidepressant-induced sexual dysfunction. Ann Pharmacother 2002;36:1577-89.
4. Clayton AH, Pradko JF, Croft HA, Montano CB, Leadbetter RA, Bolden-Watson C, et al. Prevalence of sexual dysfunction among newer antidepressants. J Clin Psychiatry 2002; 63:357-66. (Pubitemid 34456365)
5. Delgado PL, Brannan SK, Mallinckrodt CH, Tran PV, McNamara RK, Wang F, et al. Sexual functioning assessed in 4 double-blind placebo- and paroxetine-controlled trials of duloxetine for major depressive disorder. J Clin Psychiatry 2005;66:686-92. (Pubitemid 40942413)
6. Montejo-Gonzál ez AL, Llorca G, Izquierdo JA, Ledesma A, Bouso ñ o M, Calcedo A, et al. SSRI-induced sexual dysfunction: fluoxetine, paroxetine, sertraline, and fluvoxamine in a prospective, multicenter, and descriptive clinical study of 344 patients. J Sex Marital Ther 1997;23:176-94. (Pubitemid 27514710)
7. Zajecka JM. Clinical issues in long-term treatment with antidepressants. J Clin Psychiatry 2000;61(Suppl 2):20-5. (Pubitemid 30131899)
8. DeRogatis LR. Sexual function and quality of life: endpoints and outcomes. J Gen Specif Med 2001;4:35-42. (Pubitemid 34023986)
9. Clayton A, Kornstein S, Prakash A, Mallinckrodt C, Wohlreich M. Changes in sexual functioning associated with duloxetine, escitalopram, and placebo in the treatment of patients with major depressive disorder. J Sex Med 2007;4: 917-29. (Pubitemid 47082256)
10. McGahuey CA, Gelenberg AJ, Laukes CA, Moreno FA, Delgado PL, McKnight KM, Manber R. The Arizona Sexual Experience Scale (ASEX): reliability and validity. J Sex Marital Ther 2000;26:25-40. (Pubitemid 30046590)
11. American Psychiatric Association. Diagnostic and statistical manual for mental disorders. 4th ed. Text revision (DSM-IV-TR); 2000.
12. World Health Organization (WHO). International classification of diseases. 10th revision (ICD-10); 2007.
13. Guy W. ECDEU Assessment Manual for Psychopharmacology-Revised (DHEW Publ No ADM 76-338). Department of Health, Education, and Welfare, Public Health Service, Alcohol, Drug Abuse, and Mental Health Administration, NIMH Psychopharmacology Research Branch Division of Extramural Research Programs; 1976. p. 218-22.
14. Rush AJ, Trivedi MH, Ibrahim HM, Carmody TJ, Arnow B, Klein DN, et al. The 16-Item Quick Inventory of Depressive Symptomatology (QIDS), clinician rating (QIDS-C), and selfreport (QIDS-SR): a psychometric evaluation in patients with chronic major depression. Biol Psychiatry 2003;54:573-83. (Pubitemid 37289444)
15. Due ñ as H, Tapia-Paniagua G, Vazquez-Barquero JL, Acuna A, Madrigal E, Celis A, et al. The integral inventory for depression (IID), a new clinimetric tool for the emotional and physically painful dimension of depression. 2nd International Congress of the World Federation of Societies of Biological Psychiatry (WFSBP); April 17-21 Poster 02-07, Santiago, Chile; 2007.
16. EuroQol Group. EuroQol-a new facility for the measurement of health-related quality of life. Health Policy 1990;16: 199-208.
17. Sheehan DV. The Anxiety Disease, Charles Scribner & Sons, New York, 1983.
18. Rosenbaum PR, Rubin DB. The central role of the propensity score in observational studies for causal effects. Biometrika 1983;70:41-55.
19. D'Agnostino RB Jr. Tutorial in biostatistics: Propensity score methods for bias reduction in the comparison of a treatment to a non-randomized control group. Stat Med 1998;17:2265-81.
20. Thase ME, Pritchett YL, Ossanna MJ, Swindle RW, Xu J, Detke MJ. Efficacy of duloxetine and selective serotonin reuptake inhibitors: comparisons as assessed by remission rates in patients with major depressive disorder. J Clin Psychopharmacol 2007;27:672-6. (Pubitemid 351339455)
21. Fava M, Mallinckrodt CH, Detke MJ, Watkin JG, Wohlreich MM. The effect of duloxetine on painful physical symptoms in depressed patients: do improvements in these symptoms result in higher remission rates? J Clin Psychiatry 2004;65: 521-30.
22. Goldstein DJ, Lu Y, Detke MJ, Hudson J, Iyengar S, Demitrack MA. Effects of duloxetine on painful physical symptoms associated with depression. Psychosomatics 2004;45: 17-28. (Pubitemid 38082504)
23. Muñoz RA, McBride ME, Brnabic AJ, Lopez CJ, Hetem LA, Secin R, Dueñ as HJ. Major depressive disorder in Latin America: the relationship between depression severity, painful somatic symptoms, and quality of life. J Affect Disord 2005;86:93-8. (Pubitemid 40487965)
24. Russell JM, Weisberg R, Fava M, Hartford JT, Erickson JS, D'Souza DN. Efficacy of duloxetine in the treatment of generalized anxiety disorder in patients with clinically significant pain symptoms. Depress Anxiety 2008;25: E1-11.
25. Rosen RC, Lane RM, Menza M. Effects of SSRIs on sexual function: a critical review. J Clin Psychopharmacol 1999;19: 67-85. (Pubitemid 29047334)
26. Kennedy SH, Dickens SE, Eisfeld BS, Bagby RM. Sexual dysfunction before antidepressant therapy in major depression. J Affect Disord 1999 56:201-8. (Pubitemid 30058223)
27. Mallinckrodt CH, Prakash A, Andorn AC, Watkin JG, Wohlreich MM. Duloxetine for the treatment of major depressive disorder: a closer look at efficacy and safety data across the approved dose range. J Psychiatr Res 2006;40:337-48. (Pubitemid 43668983)